search
pharmaceutical industry
Trends
- 1GLP-1 drugs shift from obesity medicine to lifestyle products▼Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.
- 2MSD Starts Phase I Trial Using Cyprumed Oral Delivery Technology▼Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
Cyprumed's oral delivery technology has advanced to the clinical stage, with MSD initiating a Phase I trial to test it. The development marks the first time the platform has moved from preclinical work into human testing, a key milestone for companies working on oral delivery of drugs that are otherwise given by injection. It highlights continued industry interest in alternatives to injectable biologics.
- 3Former Pfizer CSO Bill Sessa Named Chair of Isomab's Scientific Advisory Board▼Professor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board
Professor Bill Sessa, previously Chief Scientific Officer of Internal Medicine at Pfizer, has been appointed Chair of Isomab's Scientific Advisory Board. The appointment was announced via PR Newswire. It signals Isomab's effort to strengthen its scientific leadership as it advances its development programs, bringing senior pharmaceutical industry experience to the company's advisory structure.
- 4Digital Health Platforms Still Face Major Evidence Gaps●The Evidence Gaps Digital Health Platforms Still Need to Close
A new analysis in Pharmaceutical Executive argues that digital health platforms still need to close significant gaps in clinical evidence before they can be fully trusted by regulators, payers and clinicians. It highlights concerns that many tools reach the market without robust proof of outcomes, prompting calls for better validation standards and transparency across the digital health industry.